NCT00042302终止3 期
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- QLT Inc.
- 入组人数
- 540
研究概览
简要总结
To determine whether tariquidar + combined first-line chemotherapy of paclitaxel/carboplatin in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo + paclitaxel/carboplatin. To compare the effects of tariquidar/paclitaxel/carboplatin with placebo/paclitaxel/carboplatin on tumor response, time to disease progression, performance status, symptom progression, and quality of life in patients with Stage IIIb/IV NSCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who have histologically or cytologically proven NSCLC, stage IIIb or stage IV, requiring first-line chemotherapy.
- •Patients who have a WHO performance status of 1 or 0 and life expectancy of greater than 3 months.
- •Patients who are 18 years of age or older and age of consent.
- •Patients who are women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test (serum or urine) at screening, and must be practicing an adequate method of birth control.
- •Patients who have neutrophils greater or equal to 1.5 x 103/µL; platelets greater or equal to 100 x 103/µL; bilirubin less or equal to 1.5 times the upper limit of normal or less or equal to 26 µmol/L (1.5 mg/dL); transaminases less or equal to 2.5 times the upper limit of normal or, for patients with known liver metastases, less or equal to 5 times the upper limit of normal; and creatinine less or equal to 141 µmol/L (1.6 mg/dL) or calculated creatinine clearance greater or equal to 60 mL/min prior to study treatment.
- •Patients who are able to give written informed consent and comply with the protocol.
排除标准
- •Patients who are eligible for radiotherapy or surgery for curative intent.
- •Patients who have had previous chemotherapy for NSCLC.
- •Patients who have a WHO performance status greater than
- •Patients with bronchoalveolar carcinoma (an adenocarcinoma in which cylindrical tumor cells grow upon the walls of pre-existing alveoli, from WHO histological typing of lung tumors [1]).
- •Patients who have previous or current primary malignancies at other sites within the last 5 years, with the exception of adequately treated cone-biopsied carcinoma of the cervix and basal or squamous cell skin carcinoma.
- •Patients who are a poor medical risk because of other nonmalignant systemic diseases or active uncontrolled infections.
- •Patients who have symptomatic brain metastases.
- •Patients who have peripheral neuropathy of CTC grade 2, 3, or
- •Patients who have other medical or surgical conditions that would contraindicate chemotherapy.
- •Patients who have received experimental therapies within the last 4 weeks.
- •Patients who have known hypervitaminosis or known sensitivity to ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, d-panthenol, or vitamin E.
研究者
相似试验
终止
3 期
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)Stage IIIb Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00042315QLT Inc.490
已完成
2 期
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLCCarcinoma, Non-Small Cell Lung Cancer (NSCLC)NCT02392507Eli Lilly and Company54
已完成
2 期
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteNeoplasm, Unknown PrimaryNCT00360360SCRI Development Innovations, LLC60
已完成
2 期
Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric CancerGastric CancerNCT00154778National Taiwan University Hospital55
已完成
1 期
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck CancerHead and Neck Squamous Cell CarcinomaStage IVA Oropharyngeal Carcinoma AJCC v7Stage IVB Oropharyngeal Carcinoma AJCC v7NCT01711541National Cancer Institute (NCI)24